Excelimmune (Woburn, MA) a preclinical-stage biopharmaceutical company focused on a recombinant polyclonal antibody platform for the treatment of infectious disease, closed a $4.5M Series A financing. Participants were not identified.

CytomX Therapeutics (San Francisco, CA) a development-stage biopharmaceutical company focused on protease-activated antibody therapeutics, closed a $30M Series B financing. Participants include Third Rock Ventures and Roche Venture Fund.

Alethia Biotherapeutics (Canada) a preclinical-stage biopharmaceutical company focused therapeutic monoclonal antibodies for the treatment and prevention of severe bone loss, ovarian cancer, and metastatic breast cancer, closed a $7M Series A financing, bringing the total round to $9.2M. Participants include AgeChem Venture Fund, BDC Venture Capital, GO Capital and Epicentre Technologies Corp.
Erratum: Previously identified $2.2M [...]

Igencia (Burlingame, CA) a development-stage biopharmaceutical company focused on the discovery of tumor antigens and in vivo antibody screen platforms for various oncologic indications, closed a $24M Series B financing. Participants include The Column Group, OrbiMed and 5AM Ventures.

Ablexis (San Francisco, CA) a development-stage biotechnology company focused on a transgenic mouse antibody drug discovery platform, closed a $12M Series A financing. Participants include Third Rock Ventures and Pfizer Venture Investments.

Affimed (Germany) a clinical-stage biopharmaceutical company focused on antibody therapeutics for hematological and solid tumors as well as inflammatory disease, closed a $26.4M Series C financing. Participants include Aeris Capital, BioMed Invest, Life Sciences Partners, Novo Nordisk and Orbimed.

ProtAb (Israel) a preclinical-stage biopharmaceutical company developing modulators of cytokine regulation and focused on a monoclonal antibody for the treatment rheumatoid arthritis, closed a $1.5M Series A financing. Participants include Pontifax Fund and Clal Biotechnology Industries.

OriGene Technologies (Rockville, MD) a commercial-stage gene-based reagent product company focused on cDNA and shRNA clone collections, purified human proteins, monoclonal antibodies, human tissues, multiplex assay products, antigen standards and IHC slides, closed a $16M Series B financing. Participants include IDG-Accel, SBI Ven Capital, TH Venture Capital Enterprise, Zero2IPO, Morningside and President International Development Corp..

Merus (Netherlands) a preclinical-stage biopharmaceutical focused on antibody product candidates against targets in oncology, inflammation and infectious disease, closed a $30.7M Series B financing. Participants include Novartis Option Fund, Pfizer, Bay City Capital, Life Sciences Partners and Aglaia Biomedical Ventures.

Kolltan Pharmaceuticals (New Haven, CT) a development-stage biopharmaceutical company focused on monoclonal antibody oncology therapeutics, closed a $8.5M Series B financing. Participants include Celtic Therapeutics Holdings and Tichenor Ventures.

F-star Biotech (Austria) a development-stage based biopharma company focused upon an antibody design platform, with product and indication(s) to be identified, closed a $10.8M Series A financing, bringing the total round to $25.8M. Participants include MP Healthcare Venture Management, Merck Serono Ventures, Atlas Venture, Aescap Venture, Novo Ventures and TVM Capital.

arGEN-X (Netherlands) a development-stage biopharmaceutical company focused on a monoclonal antibody platform with potential indications in autoimmunity, oncology and bone disease, closed a $4.5M Series A financing, bring total round proceeds to $18.3M. Participants have included Credit Agricole Private Equity, Forbion Capital Partners, Life Science Partners, KBC Private Equity, BioGeneration Ventures, Erasmus MC Biomedical Fund, [...]

Zyngenia (Rockville, MD) a pre-clinical stage biotherapeutics company focused on multi-specific antibodies for oncology and autoimmune disorders, closed a $10M Series A financing. Particpants include New Enterprise Associates.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb